CORDIS
EU research results

CORDIS

English EN
Optimizing a deployable high efficacy malaria vaccine

Optimizing a deployable high efficacy malaria vaccine

Objective

A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible. Leading malariologists, vaccine researchers and product developers will here collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates.
Our approach tackles the toughest problems in malaria vaccine design: choice of the best antigens, attaining high immunogenicity, avoiding polymorphic antigens and increasing the durability of vaccine immunogenicity and efficacy.
We take advantage of several recent advances in vaccinology and adopt some very new technologies: sequencing malaria peptides eluted from the HLA molecules, parasites expressing multiple transgenes, multi-antigen virus-like particles constructed with new bonding technologies, delayed release microcapsules, and liver-targeted immunisation with vaccine vectors.
We enhance our chances of success by using a multi-stage multi-antigen approach, by optimising the magnitude and durability of well-characterised immune responses to key antigens, and using stringent infectious challenges and functional assays as established criteria for progression at each stage.
The consortium comprises many of the foremost researchers in this field in Europe with leading groups in the USA, Australia and Africa. We link to EDCTP programmes and harmonise our timeline to fit with the recent roadmaps for malaria vaccine development. We include a major pharma partner and several excellent European biotech companies helping enhance Europe’s leading position in the commercial development of vaccines.
This ambitious and exciting programme should have a high chance of success in tackling the major global health problem posed by malaria.

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

Address

Wellington Square University Offices
Ox1 2jd Oxford

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 13 051 666,25

Participants (17)

Sort alphabetically

Sort by EU Contribution

Expand all

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 4 427 500

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 1 175 000

UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6

France

SORBONNE UNIVERSITE

France

EU Contribution

€ 437 500

GENOME RESEARCH LIMITED

United Kingdom

EU Contribution

€ 250 000

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT

France

EU Contribution

€ 183 775

STATENS SERUM INSTITUT

Denmark

EU Contribution

€ 250 000

UNIVERSITE DE LAUSANNE

Switzerland

NOVAVAX AB

Sweden

EU Contribution

€ 150 000

EXPRES2ION BIOTECHNOLOGIES APS

Denmark

EU Contribution

€ 25 000

IMAXIO SA

France

EU Contribution

€ 5 158,05

JAMES COOK UNIVERSITY

Australia

PROGRAM FOR APPROPRIATE TECHNOLOGYIN HEALTH

United States

EU Contribution

€ 25 000

UNITED KINGDOM RESEARCH AND INNOVATION

United Kingdom

EU Contribution

€ 25 000

MEDICAL RESEARCH COUNCIL

United Kingdom

JANSSEN VACCINES & PREVENTION BV

Netherlands

EU Contribution

€ 25 000

OSIVAX SAS

France

EU Contribution

€ 19 841,95

Project information

Grant agreement ID: 733273

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2021

Funded under:

H2020-EU.3.1.2.

  • Overall budget:

    € 23 701 228,75

  • EU contribution

    € 20 050 441,25

Coordinated by:

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom